149 related articles for article (PubMed ID: 27862647)
1. Tumor endothelial cells express high pentraxin 3 levels.
Hida K; Maishi N; Kawamoto T; Akiyama K; Ohga N; Hida Y; Yamada K; Hojo T; Kikuchi H; Sato M; Torii C; Shinohara N; Shindoh M
Pathol Int; 2016 Dec; 66(12):687-694. PubMed ID: 27862647
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells.
Ying TH; Lee CH; Chiou HL; Yang SF; Lin CL; Hung CH; Tsai JP; Hsieh YH
Sci Rep; 2016 Jul; 6():29385. PubMed ID: 27377307
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo.
Tung JN; Ko CP; Yang SF; Cheng CW; Chen PN; Chang CY; Lin CL; Yang TF; Hsieh YH; Chen KC
J Neurooncol; 2016 Sep; 129(2):201-9. PubMed ID: 27278519
[TBL] [Abstract][Full Text] [Related]
4. Pentraxin-3 and endothelial dysfunction.
Zlibut A; Bocsan IC; Agoston-Coldea L
Adv Clin Chem; 2019; 91():163-179. PubMed ID: 31331488
[TBL] [Abstract][Full Text] [Related]
5. Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells.
O'Neill CL; Guduric-Fuchs J; Chambers SE; O'Doherty M; Bottazzi B; Stitt AW; Medina RJ
Cardiovasc Res; 2016 Dec; 112(3):677-688. PubMed ID: 27659714
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12.
Margheri F; Serratì S; Lapucci A; Chillà A; Bazzichi L; Bombardieri S; Kahaleh B; Calorini L; Bianchini F; Fibbi G; Del Rosso M
Arthritis Rheum; 2010 Aug; 62(8):2488-98. PubMed ID: 20506099
[TBL] [Abstract][Full Text] [Related]
7. Systemic sclerosis-endothelial cell antiangiogenic pentraxin 3 and matrix metalloprotease 12 control human breast cancer tumor vascularization and development in mice.
Margheri F; Serratì S; Lapucci A; Anastasia C; Giusti B; Pucci M; Torre E; Bianchini F; Calorini L; Albini A; Ventura A; Fibbi G; Del Rosso M
Neoplasia; 2009 Oct; 11(10):1106-15. PubMed ID: 19794969
[TBL] [Abstract][Full Text] [Related]
8. Inducible expression of the long pentraxin PTX3 in the central nervous system.
Polentarutti N; Bottazzi B; Di Santo E; Blasi E; Agnello D; Ghezzi P; Introna M; Bartfai T; Richards G; Mantovani A
J Neuroimmunol; 2000 Jul; 106(1-2):87-94. PubMed ID: 10814786
[TBL] [Abstract][Full Text] [Related]
9. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors.
Leali D; Alessi P; Coltrini D; Ronca R; Corsini M; Nardo G; Indraccolo S; Presta M
Mol Cancer Ther; 2011 Sep; 10(9):1600-10. PubMed ID: 21764903
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of pentraxin-3 in glioblastoma cells correlates with increased invasion and IL8-VEGF signaling axis.
Wesley UV; Sutton I; Clark PA; Cunningham K; Larrain C; Kuo JS; Dempsey RJ
Brain Res; 2022 Feb; 1776():147752. PubMed ID: 34906547
[TBL] [Abstract][Full Text] [Related]
11. Oleate-induced PTX3 promotes head and neck squamous cell carcinoma metastasis through the up-regulation of vimentin.
Chan SH; Tsai JP; Shen CJ; Liao YH; Chen BK
Oncotarget; 2017 Jun; 8(25):41364-41378. PubMed ID: 28489600
[TBL] [Abstract][Full Text] [Related]
12. Long pentraxin PTX3 is upregulated systemically and centrally after experimental neurotrauma, but its depletion leaves unaltered sensorimotor deficits or histopathology.
Oggioni M; Mercurio D; Minuta D; Fumagalli S; Popiolek-Barczyk K; Sironi M; Ciechanowska A; Ippati S; De Blasio D; Perego C; Mika J; Garlanda C; De Simoni MG
Sci Rep; 2021 May; 11(1):9616. PubMed ID: 33953334
[TBL] [Abstract][Full Text] [Related]
13. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
14. Long pentraxin 3: A novel multifaceted player in cancer.
Giacomini A; Ghedini GC; Presta M; Ronca R
Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):53-63. PubMed ID: 29175552
[TBL] [Abstract][Full Text] [Related]
15. Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy.
Ronca R; Giacomini A; Di Salle E; Coltrini D; Pagano K; Ragona L; Matarazzo S; Rezzola S; Maiolo D; Torrella R; Moroni E; Mazzieri R; Escobar G; Mor M; Colombo G; Presta M
Cancer Cell; 2015 Aug; 28(2):225-39. PubMed ID: 26267536
[TBL] [Abstract][Full Text] [Related]
16. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19.
Brunetta E; Folci M; Bottazzi B; De Santis M; Gritti G; Protti A; Mapelli SN; Bonovas S; Piovani D; Leone R; My I; Zanon V; Spata G; Bacci M; Supino D; Carnevale S; Sironi M; Davoudian S; Peano C; Landi F; Di Marco F; Raimondi F; Gianatti A; Angelini C; Rambaldi A; Garlanda C; Ciccarelli M; Cecconi M; Mantovani A
Nat Immunol; 2021 Jan; 22(1):19-24. PubMed ID: 33208929
[TBL] [Abstract][Full Text] [Related]
17. IL‑1β‑induced pentraxin 3 inhibits the proliferation, invasion and cell cycle of trophoblasts in preeclampsia and is suppressed by IL‑1β antagonists.
Wang X; Zhang J; Ji J
Mol Med Rep; 2022 Apr; 25(4):. PubMed ID: 35137920
[TBL] [Abstract][Full Text] [Related]
18. The Long Pentraxin 3 Plays a Role in Bone Turnover and Repair.
Grčević D; Sironi M; Valentino S; Deban L; Cvija H; Inforzato A; Kovačić N; Katavić V; Kelava T; Kalajzić I; Mantovani A; Bottazzi B
Front Immunol; 2018; 9():417. PubMed ID: 29556234
[TBL] [Abstract][Full Text] [Related]
19. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.
Ronca R; Di Salle E; Giacomini A; Leali D; Alessi P; Coltrini D; Ravelli C; Matarazzo S; Ribatti D; Vermi W; Presta M
Mol Cancer Ther; 2013 Dec; 12(12):2760-71. PubMed ID: 24130051
[TBL] [Abstract][Full Text] [Related]
20. Tunicamycin enhances the suppressive effects of cisplatin on lung cancer growth through PTX3 glycosylation via AKT/NF-κB signaling pathway.
Ahmmed B; Khan MN; Nisar MA; Kampo S; Zheng Q; Li Y; Yan Q
Int J Oncol; 2019 Feb; 54(2):431-442. PubMed ID: 30483742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
